Granulaatiokudoksen rooli parodontaalisen regeneraation aikana

This study aims to investigate the biochemical (tissue healing and regenerative) and microbial (infectious) properties of infra- and supra- osseous granulation tissues and compare those characteristics in non-smoking and smoking periodontitis patients. To accomplish these aims, we designed 3 research objectives: 1. To compare the pro-healing and regenerative properties of infra- and supra-osseous granulation tissues harvested from non-smoking periodontitis patients using open-ended proteomics tools. 2. To describe the infectious component of infra- and supra-osseous granulation tissues harvested from non-smoking periodontitis patients using microbiome analysis. 3. To compare the effect of smoking on selected pro-healing, regenerative and virulence markers of infra-osseous granulation tissues. The main hypothesis is that infra-osseous and supra-osseous granulation tissues of smokers and non-smokers differ from each other in terms of their pro-healing, regenerative and microbial virulence properties, and infra-osseous granulation tissue is a valuable resource for tissue regeneration after periodontal treatment. The demographics of all individuals will be recorded, and full-mouth visible plaque index (PI%), probing pocket depth (PPD), clinical attachment level (CAL) and bleeding on probing (BoP%) scores from six sites of each tooth will be recorded. Periapical radiographs will be taken. Before the surgical applications, all patients will receive full-mouth scaling and root debridement. During the surgical treatment of the residual bone defects, first the supra-osseous granulation tissue samples will be collected. Afterwards, a flap will be raised, and the intra-osseous granulation tissue sample will be collected. Samples will be placed in Eppendorf tubes and will be stored at -80°C until laboratory analyses. Proteomics analysis - tissue samples will be homogenized in 100 mM ammonium bicarbonate (ABC) buffer in 2 ml reinforced tubes containing 2.8 mm ceramic (zirconium oxide) beads (Cayman Chemical) using Precellys Bead Mill Homogenizer (Bertin). Microbiome analysis - DNA will be extracted from tissue samples using the DNeasy Blood and Tissue kit following the manufacturer's recommendations (Qiagen, Germany) with minor modifications. Gel electrophoresis using Tapestation 2200 (Genomic DNA and D1000 screentapes, Agilent, USA) will be used to validate product size and purity of a subset of DNA extracts. DNA concentration will be measured using both Nanodrop and Qubit dsDNA BR Assay kit (Thermo Fisher Scientific, USA).

Targeted biochemical analysis - from all tissue samples proinflammatory (IL-1β, IL-6 and TNF-α) and anti-inflammatory (IL-4, IL-10) cytokines, macrophage-activation related chemokines (monocyte chemoattarctant protein C-C motif chemokine ligand 2 (CCL-2/MCP-1), C-C motif chemokine ligand 8 (CCL-8/ MCP-2), C-X-C motif chemokine ligand 9 (CXCL9/MIG), and C-C motif ligand 3 (CCL-3/MIP-1α)), and bone-remodeling marker (osteoprotegerin, Receptor activator of nuclear factor kappa-Β ligand (RANKL), osteocalcin, osteopontin) levels will be measured by Luminex and Simoa techniques, which can detect these markers at levels of femtogram/ml. Luminex 200 bead-based multiplex assay is available at the laboratories of Institute of Dentistry, University of Turku. Simoa HD-X analyzer is available at the laboratories of Turku University Central Hospital. Statistical analysis: Following the detection of the data distribution with the Kolmogorov-Smirnov test, repeated t-test or ANOVA in case of normal distribution will be used in the statistical analysis, and the Mann-Whitney U or Kruskal Wallis tests in case of non-normal distribution. In determining the correlation between healing and virulence marker correlations, the parametric Pearson test or the non-parametric Spearman test will be used according to the distribution. A binary logistic regression analysis with smoking, sex, and age adjustment will be conducted to assess the association between the analytes' levels and the healing response. P < 0.05 will be considered significant. Ethical approval for this project has been received from Riga Stradins University Research Ethics Committee on 28.02.2025. (2-PĒK-4/434/2025). Each patient will be informed about the research objectives and procedures both verbally and through a written informed consent form. The participants will be notified that, in accordance with patient protection laws, they have the right to withdraw from participation at any time. The participants will also be assured that withdrawing from the study will not affect their future treatment regimen with their periodontologist. Additionally, each participant will be informed that the data obtained during this research will be used to write publications in an anonymous and synthesized manner. All patient visits will be documented, and each patient will be assigned an anonymous patient number. Any necessary corrections to the medical documents will be made by crossing out the incorrect text with a single line and writing the correct text beside it. The clinician will sign next to the correction. If any side effects are observed during the study, the Ethics Committee will be notified.